Lyndsey Elizabeth Crennen, serving as the Chief Accounting Officer at Mesa Laboratories Inc. (NASDAQ:MLAB), executed a sale of 118 shares of the company's common stock on June 16, 2026. The transaction resulted in proceeds of $11,949, with each share sold at a price of $101.267. Following this transaction, Ms. Crennen's direct holdings in Mesa Laboratories common stock stand at 1,473 shares. The sale was specifically intended to cover taxes due on Restricted Stock Units (RSUs) that vested on June 15, 2026. While the stock has experienced a 25% surge over the past six months, it has since declined to $98.73.
Mesa Laboratories recently announced its fourth-quarter earnings, revealing that revenues fell short of expectations by 2%. The company faced a significant 32% decline in core revenue within its Biological Products Division, attributed to export-control related shipping delays and poor commercial execution. In response, Jefferies raised its price target for Mesa Laboratories' shares to $130 from $115, maintaining a Buy rating, indicating confidence in the company's future prospects despite recent challenges.
In other recent developments, Mesa Laboratories disclosed the planned departure of its President and CEO, Gary Owens, effective April 2026. Owens will remain in a non-executive capacity until June 2026 to assist in the transition to his successor. Furthermore, the company appointed Lyndsey Crennen as the new chief accounting officer, effective immediately. Crennen has been with Mesa Laboratories since 2018 and brings over 20 years of accounting experience to the role. According to InvestingPro analysis, MLAB appears undervalued at current levels. The platform offers 7 additional ProTips for MLAB, along with comprehensive financial metrics to help investors make informed decisions.
The transaction and recent corporate developments highlight the ongoing transition within Mesa Laboratories' leadership and the financial performance of the company in the biological products sector. The sale of shares by the Chief Accounting Officer, while routine for tax purposes, occurs amidst a period of revenue challenges and leadership changes. The company's stock performance, despite a recent surge, reflects the mixed signals from its financial results and strategic adjustments.